This review summarises important pharmacological and clinical characteristics of elbasvir/grazoprevir (Zepatier®), which is an orally-administered fixed-dose combination direct-acting anti-viral agent for use in the treatment of hepatitis C viral infection. In Australia, elbasvir/grazoprevir is registered with the Therapeutic Goods Administration (TGA) and is listed on the PBS (authority required).
The review provides commentary and recommendations from Dr Alexander Thompson, Gastroenterologist and Head of Hepatology Research at St. Vincent’s Hospital, Melbourne.
Please login below to download this issue (PDF)